International Survey on Determinants of Antibiotic Duration and Discontinuation in Pediatric Critically Ill Patients

• Published in: Pediatric critical care medicine Vol. 21; no. 9; p. e696
• Main Authors: Noël, Kim C, Papenburg, Jesse, Lacroix, Jacques, Quach, Caroline, O'Donnell, Shauna, Gonzales, Milagros, Willson, Douglas F, Gilfoyle, Elaine, McNally, James D, Reynolds, Steven, Kazzaz, Yasser, Kawaguchi, Atsushi, Sato, Masanori, Kongkiattikul, Lalida, Leteurtre, Stéphane, Dubos, François, Karaca, Yasemin, Chiusolo, Fabrizio, Piva, Jefferson, Dendukuri, Nandini, Fontela, Patricia S
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Anti-Bacterial Agents - therapeutic use; Brazil; Canada; Child; Critical Illness - therapy; Cross-Sectional Studies; France; Humans; Italy; Japan; Surveys and Questionnaires; United States; Brazil; Canada; Italy; France; United States; Japan
• ISSN: 1529-7535
• DOI: 10.1097/PCC.0000000000002397

We hypothesized that antibiotic use in PICUs is based on criteria not always supported by evidence. We aimed to describe determinants of empiric antibiotic use in PICUs in eight different countries. Cross-sectional survey. PICUs in Canada, the United States, France, Italy, Saudi Arabia, Japan, Thailand, and Brazil. Pediatric intensivists. None. We used literature review and focus groups to develop the survey and its clinical scenarios (pneumonia, septic shock, meningitis, and intra-abdominal infections) in which cultures were unreliable due to antibiotic pretreatment. Data analyses included descriptive statistics and linear regression with bootstrapped SEs. Overall response rate was 39% (482/1,251), with individual country response rates ranging from 25% to 76%. Respondents in all countries prolonged antibiotic duration based on patient characteristics, disease severity, pathogens, and radiologic findings (from a median increase of 1.8 d [95% CI, 0.5-4.0 d] to 9.5 d [95% CI, 8.5-10.5 d]). Younger age, severe disease, and ventilator-associated pneumonia prolonged antibiotic treatment duration despite a lack of evidence for such practices. No variables were reported to shorten treatment duration for all countries. Importantly, more than 39% of respondents would use greater than or equal to 7 days of antibiotics for patients with a positive viral polymerase chain reaction test in all scenarios, except in France for pneumonia (29%), septic shock (13%), and meningitis (6%). The use of elevated levels of inflammatory markers to prolong antibiotic treatment duration varied among different countries. Antibiotic-related decisions are complex and may be influenced by cultural and contextual factors. Evidence-based criteria are necessary to guide antibiotic duration and ensure the rational use of antibiotics in PICUs.